This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American Even if you have never heard of biosimilar ...
As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...
Biosimilars at the Crossroads: A $234 Billion Opportunity or a Missed Chance for Healthcare Savings?
The U.S. stands at a crossroads in light of rising drug prices and it is unclear what the future will hold in answer to the rising drug costs. Biologic medicines have rapidly expanded available ...
A new AAN position statement outlines guidelines for switching from branded biologics to biosimilars, while preserving clinical autonomy for physicians.
Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these ...
On June 10, 2025, Health Canada launched a consultation on its Draft Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs which includes numerous proposed revisions ...
Within ten years, a patient may find that even a decades-old biologic treatment option they need has no other lower-cost alternative — and the one that’s available is prohibitively expensive and not ...
Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin ...
The FDA defines a biosimilars as biologic products approved because they're highly similar to existing medicines, but there's a lot more to understand. A biosimilar is a manufactured biologic ...
The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...
India is set to become a global biopharmaceutical manufacturing hub. Finance Minister Nirmala Sitharaman announced a ...
Finance Minister Nirmala Sitharaman announces Biopharma Shakti, a ₹10,000 crore plan to boost biologics, biosimilars, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results